CD274 and renal cell carcinoma: Similarly, the consecutive Checkmate214 and Checkmate9ER trials showed the greater benefit of patients with RCC treated with combination therapies including nivolumab compared to the standard of care sunitinib, independent of the PD-L1 status of the primary tumors [3,6].